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Multi-armed Bandit Models for the
Optimal Design of Clinical Trials: Benefits
and Challenges
Sof´ıa S. Villar, Jack Bowden and James Wason
Abstract. Multi-armed bandit problems (MABPs) are a special type of
optimal control problem well suited to model resource allocation under
uncertainty in a wide variety of contexts. Since the first publication of
the optimal solution of the classic MABP by a dynamic index rule, the
bandit literature quickly diversified and emerged as an active research
topic. Across this literature, the use of bandit models to optimally de-
sign clinical trials became a typical motivating application, yet little of
the resulting theory has ever been used in the actual design and analysis
of clinical trials. To this end, we review two MABP decision-theoretic
approaches to the optimal allocation of treatments in a clinical trial:
the infinite-horizon Bayesian Bernoulli MABP and the finite-horizon
variant. These models possess distinct theoretical properties and lead
to separate allocation rules in a clinical trial design context. We eval-
uate their performance compared to other allocation rules, including
fixed randomization. Our results indicate that bandit approaches offer
significant advantages, in terms of assigning more patients to better
treatments, and severe limitations, in terms of their resulting statisti-
cal power. We propose a novel bandit-based patient allocation rule that
overcomes the issue of low power, thus removing a potential barrier for
their use in practice.
Key words and phrases: Multi-armed bandit, Gittins index, Whittle
index, patient allocation, response adaptive procedures.
1. INTRODUCTION
Randomized controlled trials have become the
gold-standard approach in clinical research over the
last 60 years. Fixing the probability of being as-
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signed to each arm for its duration, it removes
(asymptotically) any systematic differences between
patients on different arms with respect to all known
or unknown confounders. The frequentist operating
characteristics of the standard approach (e.g., the
type-I error rate and power) are well understood,
and the size of the trial can easily be chosen in ad-
vance to fix these at any level the practitioner de-
sires. However, while it is important for a clinical
trial to be adequately powered to detect a signifi-
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cant difference at its conclusion, the well-being of
patients during the study itself must not be forgot-
ten.
MABPs are an idealized mathematical decision
framework for deciding how to optimally allocate
a resource among a number of competing uses,
given that such allocation is to be done sequen-
tially and under randomly evolving conditions. In
its simplest version, the resource is work which can
further be devoted to only one use at a time. The
uses are treated as independent “projects” with a bi-
nary outcome which develop following Markov rules.
Their roots can be traced back to work produced
by Thompson (1933), which was later continued
and developed in Robbins (1952), Bellman (1956),
and finally Gittins and Jones (1974). Although their
scope is much more general, the most common sce-
nario chosen to motivate this methodology is that of
a clinical trial which has the aim of balancing two
separate goals:
• To correctly identify the best treatment (explo-
ration or learning).
• To treat patients as effectively as possible during
the trial (exploitation or earning).
One might think that these two goals are naturally
complementary, but this is not the case. Correctly
identifying the best treatment requires some pa-
tients to be assigned to all treatments, and therefore
the former acts to limit the latter.
Despite this apparent near-perfect fit between a
real-world problem and a mathematical theory, the
MABP has yet to be applied to an actual clinical
trial. Such a state of affairs was pointed out early
on by Peter Armitage in a paper reflecting upon
the use in practice of theoretical models to derive
optimal solutions for problems in clinical trials:
Either the theoreticians have got hold of
the wrong problem, or the practising trial-
lists have shown a culpable lack of aware-
ness of relevant theoretical developments,
or both. In any case, the situation does
not reflect particularly well on the statisti-
cal community (Armitage, 1985, page 15).
A very similar picture is described two decades
later in Palmer (2002) when discussing and ad-
vocating for the use of “learn-as-you-go” designs
as a means of alleviating many problems faced by
those involved with clinical trials today. More re-
cently, Don Berry—a leading proponent of the use
of Bayesian methods to develop innovative adaptive
clinical trials—also highlighted the resistance to the
use of bandit theoretical results:
But if you want to actually use the result
then people will attack your assumptions.
Bandit problems are good examples. An
explicit assumption is the goal to treat pa-
tients effectively, in the trial as well as out.
That is controversial ( . . . ) (Stangl, Inoue
and Irony, 2012).
In view of this, a broad goal of this article is
to contribute to setting the ground for change by
reviewing a concrete area of theoretical bandit re-
sults, in order to facilitate their application in prac-
tice. The layout of the paper is as follows: In Sec-
tion 2 we first recount the basic elements of the
Bayesian Bernoulli MABP. In Section 3 we focus
on the infinite-horizon case, presenting its solution
in terms of an index rule—whose optimality was
first proved by Gittins and Jones over 30 years ago.
In Section 4 we review the finite horizon variant
by reformulating it as an equivalent infinite-horizon
restless MABP, which further provides a means to
compute the index rule for the original problem. In
Section 5 we compare, via simulation, the perfor-
mance of the MABP approaches to existing meth-
ods of response adaptive allocation (including stan-
dard randomization) in several clinical trial settings.
These results motivate the proposal of a compos-
ite method, that combines bandit-based allocation
for the experimental treatment arms with standard
randomization for the control arm. We conclude in
Section 6 with a discussion of the existing barriers
to the implementation of bandit-based rules for the
design of clinical trials and point to future research.
2. THE BAYESIAN BERNOULLI
MULTI-ARMED BANDIT PROBLEM
The Bayesian Bernoulli K-armed bandit problem
corresponds to a MABP in which only one arm
can be worked on at a time t, and work on arm
k = 1, . . . ,K represents drawing a sample observa-
tion from a Bernoulli population Yk,t with unknown
parameter pk, “earning” the observed value yk,t as a
reward (i.e., either 0 or 1). In a clinical trial context,
each arm represents a treatment with an unknown
success rate. The Bayesian feature is introduced by
letting each parameter pk have a Beta prior with
parameters sk,0 and fk,0 such that (sk,0, fk,0) ∈ N
2
+
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before the first sample observation is drawn (i.e., at
t = 0). After having observed Sk,t = sk,t successes
and Fk,t = fk,t failures, with (Sk,t, Fk,t) ∈N
2
0 for any
t ≥ 1, the posterior density is a Beta distribution
with parameters (sk,0 + sk,t, fk,0+ fk,t).
Formally, the Bernoulli Bayesian MABP is de-
fined by letting each arm k be a discrete-time
Markov Control Process (MCP) with the following
elements:
(a) The state space: Xk,t = {(sk,0 + Sk,t, fk,0 +
Fk,t) ∈N
2
+ : Sk,t+Fk,t ≤ t, for t= 0,1, . . . , T} which
represents all the possible two-dimensional vectors
of information on the unknown parameter pk at time
t. We denote the available information on treatment
k at time t as xk,t = (sk,0+ Sk,t, fk,0+Fk,t) and the
initial prior as xk,0 = (sk,0, fk,0). In a clinical trial
context, the random vector (Sk,t, Fk,t) represents the
number of successful and unsuccessful patient out-
comes (e.g., response to treatment, remission of tu-
mor, etc.).
(b) The action set Ak is a binary set represent-
ing the action of drawing a sample observation from
population k at time t (ak,t = 1) or not (ak,t = 0).
In a clinical context, the action variable stands for
the choice of assigning patient t to treatment arm k
or not.
(c) The Markovian transition law Pk(xk,t+1|xk,t,
ak) describing the evolution of the information state
variable in population k from time t to t + 1 is
given by
xk,t+1 =


(sk,0+ sk,t+ 1, fk,0+ fk,t),
if ak,t = 1
w.p.
sk,0+ sk,t
sk,0+ fk,0+ sk,t+ fk,t
,
(sk,0+ sk,t, fk,0+ fk,t+1),
if ak,t = 1
w.p.
fk,0+ fk,t
sk,0+ fk,0+ sk,t+ fk,t
,
xk,t,
if ak,t = 0 w.p. 1,
(2.1)
for any xk,t ∈ Xk,t and where w.p. stands for “with
probability.”
(d) The expected rewards and resource consump-
tion functions are
R(xk,t, ak,t) =
sk,0+ sk,t
sk,0+ fk,0+ sk,t+ fk,t
ak,t,
(2.2)
C(xk,t, ak,t) = ak,t,
for t= 0,1, . . . , T − 1, where, in accordance to (2.1),
a reward (i.e., a treatment success) in arm k arises
only if that arm is worked on and with a probability
given by the posterior predictive mean of pk at time
t and resource consumption is restricted by the fact
that (at most) one treatment can be allocated to
every patient in the trial, that is,
∑K
k=1 ak,t ≤ 1 for
all t.
A rule is required to operate the resulting MCP,
indicating which action to take for each of the K
arms, for every possible combination of information
states and at every time t, until the final horizon T .
Such a rule forms a sequence of actions {ak,t}, which
depends on the information available up to time t,
that is, on {xk,t}, and it is known as a policy within
the Markov Decision Processes literature. To com-
plete the specification of this multi-armed bandit
model as an optimal control model, the problem’s
objective function must be selected. Given an ob-
jective function and a time horizon, a multi-armed
bandit optimal control problem is mathematically
summarized as the problem of finding a feasible pol-
icy, pi, in Π (the set of all the feasible policies given
the resource constraint) that optimizes the selected
performance objective.
The performance objective in the Bayesian
Bernoulli MABP is to maximize the Expected To-
tal Discounted (ETD) number of successes after T
observations, letting 0 ≤ d < 1 be the discount fac-
tor. Then, the corresponding bandit optimization
problem is to find a discount-optimal policy such
that
V ∗D(x˜0)
=max
pi∈Π
E
pi
[
T−1∑
t=0
K∑
k=1
dt
sk,0+ Sk,t
sk,0+ fk,0+ Sk,t +Fk,t
(2.3)
· ak,t
∣∣∣x˜0 = (xk,0)Kk=1
]
,
where x˜0 is the initial joint state, E
pi[·] denotes ex-
pectation under policy pi and transition probabil-
ity rule (2.1), V ∗D(x˜0) is the optimal expected to-
tal discounted value function conditional on the ini-
tial joint state being equal to x˜0 (for any possible
joint initial state), and where, given the resource
constraint, the family of admissible feasible policies
Π contains the sampling rules pi for which it holds
that
∑K
k=1 ak,t ≤ 1 for all t.
A generic MABP formally consists of K discrete-
time MCPs with their elements defined in more gen-
erality, that is, (a) the state space: a Borel space,
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(b) the binary action set, (c) the Markovian transi-
tion law : a stochastic kernel on the state space given
each action and (d) a reward function and a work
consumption function: two measurable functions. As
before, the MABP is to find a policy that optimizes
a given performance criterion, for example, it max-
imizes the ETD net rewards.
Robbins (1952) proposed an alternative version of
the Bayesian Bernoulli MABP problem by consid-
ering the average regret after allocating T sample
observations [for a large T and for any given and un-
known (pk)
K
k=1]. For the Bayesian Bernoulli MABP,
the total regret ρ is defined as
ρ= T max
k
{pk} − E
pi
[
T−1∑
t=0
K∑
k=1
ak,tYk,t
]
(2.4)
for some (pk)
K
k=1.
A form of asymptotic optimality can be defined
for sampling rules pi in terms of (2.4) if it holds that
for any (pk)
K
k=1, limT→∞
ρ
T
= 0. A necessary condi-
tion for a rule to attain this property is to sample
each of the K populations infinitely often, that is,
to continue to sample from (possibly) suboptimal
arms for every t <∞. In other words, asymptotically
optimal rules have a strictly positive probability of
allocating a patient to every arm at any point of
the trial. Of course, within the set of asymptotically
optimal policies secondary criteria may be defined
and considered (see, e.g., Lai and Robbins, 1985).
As it will be illustrated in Section 5, objectives in
terms of (2.3) or (2.4) give rise to sampling rules
with distinct statistical properties. Asymptotically
optimal rules, that is, in terms of (2.4), maximize
the learning about the best treatment, provided it
exists, while the rules that are optimal in terms of
(2.3) maximize the mean number of total successes
in the trial.
3. THE INFINITE-HORIZON CASE: A
CLASSIC MABP
We now review the solution giving the optimal
policy to optimization problem (2.3) in the infinite-
horizon setting by letting T = ∞. In general, as
MABPs are a special class of MCPs, the traditional
technique to address them is via a dynamic pro-
gramming (DP) approach. Thus, the solution to
(2.3), according to Bellman’s principle of optimality
(Bellman, 1952), is such that for every t = 0,1, . . .
Fig. 1. The number of individual computations for an ap-
proximation to the optimal rule in a particular instance of the
Bayesian Bernoulli MABP as a function of T with K = 3 and
d= 0.9 for the Brute force, DP and Gittins index approaches.
the following DP equation holds:
V ∗D(x1,t, . . . ,xK,t)
=max
k
{
sk,0+ sk,t
sk,0+ fk,0+ sk,t+ fk,t
+ d
(
sk,0+ sk,t
sk,0+ fk,0+ sk,t+ fk,t
(3.1)
· V ∗D(x1,t,xk,t+ e1, . . . ,xK,t)
+
fk,0+ fk,t
sk,0+ fk,0+ sk,t+ fk,t
· V ∗D(x1,t,xk,t + e2, . . . ,xK,t)
)}
,
where e1, e2 respectively denote the unit vectors
(1,0) and (0,1). Under the assumptions defining
the Bayesian Bernoulli MABP, the theory for dis-
counted MCPs ensures the existence of an optimal
solution to (3.1) and also the monotone convergence
of the value functions V ∗D(x˜t). Therefore, equation
(3.1) can be approximately solved iteratively using
a backward induction algorithm.
Unfortunately, as shown in Figure 1, such a DP
technique suffers from a severe computational bur-
den, which is particularly well illustrated in the clas-
sic MABP where the size of the state space grows
with the truncation horizon T . To illustrate this
fact, consider the case of K treatments with an
initial uniform prior distribution (i.e., sk,0 = fk,0 =
1 ∀k) and truncation horizon to initialize the algo-
rithm equal to T . The total number of individual
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calculations [i.e., the number of successive evalua-
tions of V ∗D(x1,t, . . . ,xK,t)] required to find an ap-
proximate optimal solution by means of the DP
algorithm equals (T−1)!(2K)!(T−2K−1)! . The precision of
such an approximation depends on d, for example,
if d ≤ 0.9 values to four-figure accuracy are calcu-
lated for T ≥ 100. Therefore, considering the prob-
lem with K = 3 and d = 0.9 (and hence T ≥ 100)
makes the intractability of the problem’s optimal
policy become evident. (For a more detailed discus-
sion see the Appendix.)
3.1 The Gittins Index Theorem
The computational cost of the DP algorithm to
solve equation (3.1) is significantly smaller than the
cost of a complete enumeration the set of feasible
policies Π (i.e., the brute force strategy), yet it is
still not enough to make the solution of the problem
applicable for most real world scenarios, with more
than 2 treatment arms. For this reason the problem
gained the reputation of being extremely hard to
solve soon after being formulated for the first time,
becoming a paradigmatic problem to describe the
exploration versus exploitation dilemma character-
istic of any data-based learning process.
Such a state of affairs explains why the solution
first obtained by Gittins and Jones (1974) consti-
tutes such a landmark event in the bandit litera-
ture. The Index theorem states that if problem P is
an infinite-horizon MABP with each of its K com-
posing MCPs having (1) a finite action set Ak, (2)
a finite or infinite numerable state space Xk, (3) a
Markovian transition law under the passive action
ak,t = 0 (i.e., the passive dynamics) such that
Pk(x
′
k|xk,0) = Pk{Xk,t+1 = x
′
k|Xk,t = xk, ak,t = 0}
(3.2)
= 1{xk′=xk},
for any xk, x
′
k ∈ Xk, where 1{xk′=xk} is an indicator
variable for the event that the state variable value at
time t+1: xk′ equals the state variable value of state
t: xk, and (4) the set of feasible polices Π contains
all polices pi such that for all t
K∑
k=1
ak,t ≤ 1,(3.3)
then there exists a real-valued index function G(xk,t),
which recovers the optimal solution to such a MABP
when the objective function is defined under a ETD
criterion, as in (2.3). Such a function is defined as
follows:
Gk(xk,t) = sup
τ≥1
EXk,t=xk,t
∑τ−1
i=0 R(Xk,t+i,1)d
i
EXk,t=xk,t
∑τ−1
i=0 C(Xk,t+i,1)d
i
,(3.4)
where the expectation is computed with respect to
the corresponding Markovian (active) transition law
Pk(x
′
k|xk,1), and τ is a stopping time. Specifically,
the optimal policy pi∗ for problem P is to work on
the bandit process with the highest index value,
breaking ties randomly. Note that the stopping time
τ is past-measurable, that is, it is based on the in-
formation available at each decision stage only. Ob-
serve also that the index is defined as the ratio of
the ETD reward up to τ active steps to the ETD
cost up to τ active steps.
MABPs whose dynamics are restricted as in (3.2)
(namely, those in which passive projects remain
frozen in their states) are referred to in the spe-
cialized literature as classic MABPs and the name
Gittins index is used for the function (3.4). The In-
dex theorem’s significant impact derives from the
possibility of using such a result to break the curse
of dimensionality by decomposing the optimal so-
lution to a K-armed MABP in terms of its inde-
pendent parts, which are remarkably more tractable
than the original problem as shown in Figure 1. The
number of individual calculations required to solve
problem (3.1) using the Index theorem is of order
1
2(T − 1)(T − 2), which no longer explodes with the
truncation horizon T . Further, it is completely inde-
pendent of K, which means that a single index table
suffices for all possible trials, therefore reducing the
computing requirements appreciably. (For more de-
tails, see the Appendix.)
Such computational savings are particularly well
illustrated in the Bayesian Bernoulli MABP where
the Gittins index (3.4) is given by
Gk(xk,t) = sup
τ≥1
E
·
∑τ−1
i=0
sk,0+Sk,t+i
sk,0+fk,0+Sk,t+i+Fk,t+i
di
E
·
∑τ−1
i=0 d
i
,(3.5)
where E
·
= EXk,t=(sk,0+sk,t,fk,0+fk,t).
Calculations of the indices (3.5) have been re-
ported in brief tables as in Gittins (1979) and Robin-
son (1982). Improvements to the efficiency of this
computing the index have since been proposed by
Katehakis and Veinott (1985), Katehakis and Der-
man (1986). Moreover, since the publication of Git-
tins’ first proof of the optimality result of the in-
dex policy for a classic MABP in Gittins and Jones
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Table 1
The (approximate) Gittins index values for an information
vector of s0 + st successes and f0 + ft failures, where
d= 0.99 and T is truncated at T = 750
f/s 1 2 3 4 5 6
1 0.8699 0.9102 0.9285 0.9395 0.9470 0.9525
2 0.7005 0.7844 0.8268 0.8533 0.8719 0.8857
3 0.5671 0.6726 0.7308 0.7696 0.7973 0.8184
4 0.4701 0.5806 0.6490 0.6952 0.7295 0.7561
5 0.3969 0.5093 0.5798 0.6311 0.6697 0.6998
6 0.3415 0.4509 0.5225 0.5756 0.6172 0.6504
(1974), there have been alternative proofs, each of-
fering complementary insights and interpretations.
Among them, the proofs by Whittle (1980), Varaiya,
Walrand and Buyukkoc (1985), Weber (1992) and
Bertsimas and Nin˜o-Mora (1996) stand out.
To elaborate a little more on the use of the Git-
tins index for solving a K-armed Bayesian Bernoulli
MABP in a clinical trial context, we have included
some values of the Gittins index in Table 1 and Fig-
ure 2. These values correspond to a particular in-
stance in which the initial prior for every arm is uni-
form, the discount factor is d= 0.99, the index pre-
cision is of 4 digits and we have truncated the search
Fig. 2. The (approximate) Gittins index values for an infor-
mation vector of s0 + st successes and f0 + ft failures, where
d= 0.99 and T is truncated at T = 750.
of the best stopping time to T = 750. The choice of
d = 0.99 is a widely used value in the related ban-
dit literature. In our example, since 0.99750 < 10−3,
patients treated after this time yield an almost zero
expected discounted reward and are hence ignored.
The Gittins index policy assigns a number to ev-
ery treatment (from an extended version of Table 1)
based on the values of sk,t and fk,t observed, and
then prioritizes sampling the one with the highest
value. Thus, provided that we adjust for each treat-
ment prior, the same table can be used for mak-
ing the allocation decision of all treatments in a
trial. Furthermore, the number of treatments need
not be prespecified in advance and new treatments
may be seamlessly introduced part way through the
trial as well (see Whittle, 1981). To give a concrete
example, suppose that all treatments start with a
common uniform prior, then all initial states are
equal to xk,0 = (1,1) with a corresponding Gittins
index value of 0.8699 for all of them. Yet, if a treat-
ment k has a beta prior with parameters (1,2) and
another treatment k′ has a prior with parameters
(2,1), their respective initial states are xk,0 = (1,2)
and xk′,0 = (2,1), and their associated index values
respectively are 0.7005, 0.9102. The same reasoning
applies for the case in which priors combine with
data so as to have xk,1 = (1,2) and xk′,1 = (2,1).
The underlined values in Table 1 describe situ-
ations in which the learning element plays a key
role. Consider two treatments with the same pos-
terior mean of success 2/4 = 4/8 = 1/2. Accord-
ing to the indices denoted by the single line, the
treatment with the smallest number of observa-
tions is preferred: 0.7844 > 0.6952. Moreover, con-
sider the case in which the posterior means of suc-
cess suggest the superiority of one over the other:
2/5 = 0.4< 6/12 = 0.5, yet their indices denoted by
the double-underline suggest the opposite, 0.6726>
0.6504, again prioritizing the least observed popula-
tion.
Gittins and Wang (1992) define the learning com-
ponent of the index as the difference between the
index value and the expected immediate reward,
which for the general Bayesian Bernoulli MABP is
given by
sk,0+sk,t
sk,0+fk,0+sk,t+fk,t
. This posterior probabil-
ity is the current belief that a treatment k is success-
ful and it can be used for making patient allocation
decisions in a myopic way, that is, exploiting the
available information without taking into account
the possible future learning. Consider, for instance,
the case where xk,0 = (1,1) for all k. In that case, the
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learning component before making any treatment al-
location decision is thus (0.8699− 0.5) = 0.3699. As
the number of observations of a bandit increases, the
learning part of the indices decreases.
4. THE FINITE HORIZON CASE: A
RESTLESS MABP
Of course, clinical trials are not run with infi-
nite resources or patients. Rather, one usually at-
tempts to recruit the minimum number of patients
to achieve a pre-determined power. Thus, we now
consider the optimization problem defined in (2.3)
for a finite value of T . Indeed, a solution could in
theory be obtained via DP, but it is impractical
in large-scale scenarios for reasons already stated.
Moreover, the Index theorem does not apply to this
case, thus, the Gittins index function as defined for
the infinite-horizon variant does not exist (Berry
and Fristedt, 1985). In the infinite-horizon prob-
lem, at any t there is always an infinite number
of possible sample observations to be drawn from
any of the populations. This is no longer the case
in a finite-horizon problem, and the value of a sam-
pling history (sk,t, fk,t) is not the same when the
sampling process is about to start than when it is
about to end. The finite-horizon problem analysis
is thus more complex, because these transient ef-
fects must be considered for the characterization of
the optimal policy. In what follows we summarize
how to derive an index function analogous to Git-
tins’ rule for the finite-horizon Bayesian Bernoulli
MABP based on an equivalent reformulation of it as
an infinite-horizon Restless MABP, as it was done
in Nin˜o-Mora (2005). In the equivalent model the
information state is augmented, adding the number
of remaining sample observations that can be drawn
from the K populations. Hence, the MCP has the
following modified elements:
(a) An augmented state space˜ Xk given by the
union of the set Xk,t × T, where T = {0,1, . . . , T},
and an absorbing state {E}, representing the end of
the sampling process. Thus, xˆk,t = (xk,t, T − t) is a
three-dimensional vector combining the information
on the treatment (prior and observed) and the num-
ber of remaining patients to allocate until the end
of the trial.
(b) The same as in Section 2.
(c) A transition law Pk(xˆk,t+1|xˆk,t, ak) for every
xˆk,t such that 0≤ t≤ T − 1:
xˆk,t+1
(4.1)
=


if ak,t = 1 :
(sk,0+ sk,t+1, fk,0+ fk,t, T − (t+ 1)),
w.p.
sk,t+ sk,0
sk,t+ fk,t+ sk,0+fk,0
,
(sk,0+ sk,t, fk,0+ fk,t+1, T − (t+ 1)),
w.p.
fk,t+ fk,0
sk,t+ fk,t+ sk,0+ fk,0
,
if ak,t = 0 (xk,t, T − (t+1)),
w.p. 1,
xˆk,T and E, under both actions, lead to E with prob-
ability one.
(d) The one-period expected rewards and re-
source consumption functions are defined as in (2.2)
for t = 0,1, . . . , T − 1, while the states E and xˆk,T
both yield 0 reward and work consumption.
The objective in the resulting bandit optimiza-
tion problem is also to find a discount-optimal policy
that maximizes the ETD rewards.
4.1 Restless MABPs and the Whittle Index
In this equivalent version the horizon is infinite
(a fiction introduced by forcing every arm of the
MABP to remain in state E after the period T ),
nonetheless, the Index theorem does not apply to it
because its dynamics do not fulfil condition (3.2).
The inclusion of the number of remaining observa-
tions to allocate as a state variable causes inactive
arms to evolve regardless of the selected action, and
this particular feature makes the augmented MABP
restless.
In the seminal work by Whittle (1988), this par-
ticular extension to the MABP dynamics was first
proposed and the name restless was introduced to
refer to this class of problems. Whittle deployed a
Lagrangian relaxation and decomposition approach
to derive an index function, analogous to the one
Gittins had proposed to solve the classic case, which
has become known as the Whittle index.
One of the main implications of Whittle’s work is
the realization that the existence of such an index
function is not guaranteed for every restless MABP.
Moreover, even in those cases in which it exists, the
index rule does not necessarily recover the optimal
solution to the original MABP (as it does in the
classic case), being thus a heuristic rule. Whittle fur-
ther conjectured that the index policy for the rest-
less variant enjoys a form of asymptotic optimality
(in terms of the ETD rewards achieved), a property
later established by Weber and Weiss (1990) under
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certain conditions. Typically, the resulting heuris-
tic has been found to be nearly optimal in various
models.
4.2 Indexability of Finite-Horizon Classic MABP
In general, establishing the existence of an index
function for a restless MABP (i.e., showing its index-
ability) and computing it is a tedious task. In some
cases, the sufficient indexability conditions (SIC) in-
troduced by Nin˜o-Mora (2001) can be applied for
both purposes.
The restless bandit reformulation of finite-horizon
classic MABPs, as defined in Section 2, is always
indexable. Such a property can either be shown by
means of the SIC approach or simply using the sem-
inal result in Bellman (1956), by which the mono-
tonicity of the optimal policies can be ensured, al-
lowing to focus attention on a nested family of stop-
ping times.
Moreover, the fact that in this restless MABP re-
formulation the part of the augmented state that
continues to evolve under ak,t = 0, that is, T − t,
does so in the exact same way that under ak,t = 1
allows computation of the Whittle index as a modi-
fied version of the Gittins index, in which the search
of the optimal stopping time in (3.4) is truncated to
be less than or equal to the number of remaining
observations to allocate (at each decision period)
(see Proposition 3.1 in Nin˜o-Mora, 2011). Hence,
the Whittle index for the finite-horizon Bayesian
Bernoulli MABP is
Wk(xˆk,t) = sup
1≤τ≤T−t
E
Xˆk,t=xˆk,t
∑τ−1
i=0 R(Xˆk,t+i,1)d
i
E
Xˆk,t=xˆk,t
∑τ−1
i=0 C(Xˆk,t+i,1)d
i
,
(4.2)
for xˆk,t ∈˜Xk \ {E, xˆk,T },
where the expectation is computed with respect to
the corresponding Markovian (active) transition law
Pk(xˆk,t+1|xˆk,t,1) and τ is a stopping time.
Table 2, Table 3 and Table 4 include some values
of the Whittle indices for instances in which, as be-
fore, the initial prior is uniform for all the arms and
the index precision is of 4 digits, but the discount
factor is d = 1, the sampling horizon is set to be
T = 180, and the number of remaining observations
is respectively allowed to be T − t= 80, T − t= 40
and T − t = 1. Again, the Whittle index rule as-
signs a number from these tables to every treatment,
based on the values of sk,0+ sk,t and fk,0+ fk,t and
on the number of remaining periods T − t, and then
prioritizes sampling the one with the highest value.
Table 2
The Whittle index values for an information vector of
s0 + st successes and f0 + ft failures, T − t= 80, d= 1 and
where the size of the trial is T = 180
f/s 1 2 3 4 5 6
1 0.8558 0.9002 0.9204 0.9326 0.9409 0.9471
2 0.6803 0.7689 0.8140 0.8423 0.8621 0.8769
3 0.5463 0.6552 0.7158 0.7565 0.7855 0.8077
4 0.4503 0.5630 0.6335 0.6812 0.7167 0.7444
5 0.3786 0.4923 0.5642 0.6169 0.6565 0.6876
6 0.3247 0.4348 0.5073 0.6040 0.6040 0.6380
It follows from the above tables that the learning
element of this index decreases as T − t decreases.
In the limit, when T − t = 1 the Whittle index is
exactly the posterior mean of success (which cor-
responds to the myopic allocation rule that results
from using current belief as an index). On the con-
trary, as T − t→∞, the Whittle index tends to
approximate the Gittins index. Hence, for a given
information vector, the relative importance of ex-
ploring (or learning) vs. exploiting (or being my-
opic) varies significantly over time in a finite-horizon
problem as opposed to the infinite-horizon case in
which this balance remains constant in time depend-
ing solely on the sampling history. Notice that the
computational cost of a single Whittle index table
is, at most, the same as for a Gittins index one; how-
ever, solving a finite horizon MABP using the Whit-
tle rule has significantly higher computational cost
than the infinite-horizon case, because the Whittle
indices must be computed at every time point t.
This evolution of the learning vs. earning trade-
off is depicted graphically in Figure 3 and causes
the decisions in each of the highlighted situations of
Table 1 to change over time when considered for a
finite-horizon problem. In Table 2 with T − t = 80
both decisions coincide with the ones described for
Table 3
The Whittle index at T − t= 40
f/s 1 2 3 4 5 6
1 0.8107 0.8698 0.8969 0.9132 0.9244 0.9326
2 0.6199 0.7239 0.7778 0.8120 0.8360 0.8539
3 0.4877 0.6067 0.6753 0.7214 0.7546 0.7802
4 0.3955 0.5157 0.5920 0.6447 0.6837 0.7147
5 0.3297 0.4476 0.5231 0.5802 0.6233 0.6573
6 0.2805 0.3929 0.4690 0.5254 0.571 0.6075
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Table 4
The Whittle index at T − t= 1
f/s 1 2 3 4 5 6
1 0.5000 0.6667 0.7500 0.8000 0.8333 0.8571
2 0.3333 0.5000 0.6000 0.6667 0.7143 0.7500
3 0.2500 0.4000 0.5000 0.5714 0.6250 0.6667
4 0.2000 0.3333 0.4286 0.5000 0.5556 0.6000
5 0.1667 0.2857 0.3750 0.4444 0.5000 0.5455
6 0.1429 0.2500 0.3333 0.4000 0.4545 0.5000
Table 1, while in Table 3, in which T − t= 40, the
decision for the second example has changed, and in
Table 4, in which T − t = 1, the decisions in both
cases are different.
5. SIMULATION STUDY
In this section we evaluate the performance of a
range of patient allocation rules in a clinical trial
context, including the bandit-based solutions of Sec-
tion 3 and Section 4. We focus on the following:
statistical power (1− β); type-I error rate (α); ex-
pected proportion of patients in the trial assigned to
the best treatment (p∗); expected number of patient
successes (ENS); and, for the two-arm case, bias in
Fig. 3. The (approximate) Whittle index values for an infor-
mation vector of s0+ st successes and f0+ ft failures, plotted
for T − t ∈ {1,40,80} with d= 1 and T = 180.
the maximum likelihood estimate of treatment ef-
fect associated with each decision rule. Specifically,
we investigate the following patient allocation pro-
cedures:
• Fixed Randomized design (FR): uses an equal,
fixed probability to allocate patients to each arm
throughout the trial.
• Current Belief (CB): allocates each patient to the
treatment with the highest mean posterior prob-
ability of success.
• Thompson Sampling (TS): randomizes each pa-
tient to a treatment k with a probability that
is proportional to the posterior probability that
treatment k is the best given the data. In the sim-
ulations we shall use the allocation probabilities
defined as
pik,t = P(ak,t = 1|xk,t)
(5.1)
=
P(maxi pi = pk|xk,t)
c∑K
k=1P(maxi pi = pk|xk,t)
c
,
where c is a tuning parameter defined as t2T , and
t and T are the current and maximum sample size
respectively. See, for example, Thall and Wathen
(2007).
• Gittins index (GI) and Whittle index (WI): re-
spectively use the corresponding index functions
defined by formulae (3.5) and (4.2).
• Upper Confidence Bound index (UCB): developed
by Auer, Cesa-Bianchi and Fischer (2002), takes
into account not only the posterior mean but
also its variability by allocating the next patient
to the treatment with the highest value of an
index, calculated as follows:
sk,0+sk,t
sk,0+fk,0+sk,t+fk,t
+√
2 log t
sk,0+fk,0+sk,t+fk,t
.
Semi-Randomized (Asymptotically Optimal) Ban-
dit Approaches In addition, we consider a random-
ized class of index-based bandit patient allocation
procedures based on a simple modification first sug-
gested in Bather (1981). The key idea is to add small
perturbations to the index value corresponding to
the observed data at each stage, obtaining a new
set of indices in which the (deterministic) index-
based part captures the importance of the exploita-
tion based on the accumulated information and the
(random) perturbation part captures the learning
element. Formally, these rules are defined as follows:
I(sk,0+ sk,t, fk,0+ fk,t)
(5.2)
+Zt ∗ λ(sk,0+ sk,t+ fk,t+ fk,0),
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where I(sk,0+ sk,t, fk,0+ fk,t) is the index value as-
sociated to the prior and observed data on arm k
by time t, Zt is an i.i.d. positive and unbounded
random variable, and λ(sk,0 + sk,t + fk,t+ fk,0) is a
sequence of strictly positive constants tending to 0
as sk,0 + sk,t + fk,t + fk,0 tends to ∞. The interest
in this class of rules is due to their asymptotic opti-
mality, that is, property (2.4) discussed in Section 2,
specifically on assessing how their performance com-
pares to the index rules that are optimal (or nearly
optimal) in terms of the ETD objective (2.3). Notice
that rules defined by (5.2) have a decreasing, though
strictly positive, probability of allocating patients to
every arm at any point of the trial. In other words,
rules (5.2) are such that most of the patients are
allocated sequentially to the current best arm (ac-
cording to the criteria given by the index value),
while some patients are allocated all the other of
the treatment arms.
For the simulations included in this paper we let
Zt(K) be an exponential random variable with pa-
rameter 1
K
; λ(sk,0+sk,t+fk,t+fk,0) =
K
sk,0+sk,t+fk,t+fk,0
and define two additional approaches:
• Randomized Belief index (RBI) design: makes the
sampling decisions between the populations based
on an index computed setting I(sk,0 + sk,t, fk,t +
fk,0) =
sk,0+sk,t
sk,0+fk,0+sk,t+fk,t
in (5.2).
• Randomized Gittins index (RGI) design: first sug-
gested in Glazebrook (1980), makes the sampling
decisions between the populations based on the
index computed setting I(sk,0+ sk,t, fk,t+ fk,0) =
G(sk,0+ sk,t, fk,t+ fk,0) in (5.2).
For every design, ties are broken at random and in
every simulated scenario we let xk,0 = (sk,0, fk,0) =
(1,1) for all k.
Design Scenarios We implement all of the above
methods in several K-arm trial design settings. In
each case, trials are made up of K − 1 experimental
treatments and one control treatment. The control
group (and its associated quantities) is always de-
noted by the subscript 0 and the experimental treat-
ment groups by 1, . . . ,K − 1. We first consider the
case K = 2. To compare the two treatments, we con-
sider the following hypothesis: H0 : p0 ≥ p1, with the
type-I error rate calculated at p0 = p1 = 0.3 and the
power to reject H0 calculated at H1 : p0 = 0.3;p1 =
0.5. We set the size of the trial to be T = 148 to
ensure that FR will attain at least 80% power when
rejecting H0 with a one-sided 5% type-I error rate.
We then evaluate the performances of these designs
by simulating 104 repetitions of the trials under each
hypothesis and comparing the resulting operating
characteristics of the trials. Hypothesis testing is
performed using a normal cutoff value (when ap-
propriate) and using an adjusted Fisher’s exact test
for comparing two binomial distributions, where the
adjustment chooses the cutoff value to achieve a 5%
type-I error.
For the K-arm design settings we shall con-
sider the following hypothesis: H0 : p0 ≥ pi for i =
1, . . . ,K − 1 with the family-wise error rate calcu-
lated at p0 = p1 = · · ·= pK−1 = 0.3. We use the Bon-
ferroni correction method to account for multiple
testing and therefore ensure that the family-wise er-
ror rate is less than or equal to 5%, that is, all hy-
potheses whose p-values pk are such that pk <
α
K−1
are rejected. Additionally, when there are multiple
experimental treatments, we shall define the statisti-
cal power as the probability of the trial ending with
the conclusion that a truly effective treatment is ef-
fective.
5.1 Two-Arm Trial Setting Simulations
Table 5 shows the results forK = 2 under both hy-
potheses and for each proposed allocation rule. The
randomized and semi-randomized response-adaptive
procedures (i.e., TS, UCB, RBI and RGI) exhibit a
slightly inferior power level than a FR design; how-
ever, they have an advantage in terms of ENS over
a FR design. On the other hand, the three deter-
ministic index-based approaches (i.e., CB, WI and
GI) have the best performance in terms of ENS, yet
result in power values which are far below the re-
quired values. In the most extreme case, for the CB
and WI rules, the power is approximately 3.5 times
smaller than with a FR design.
Adaptive rules have their power reduced because
they induce correlation among treatment assign-
ments; however, for the deterministic index policies
this effect is the most severe because they perma-
nently skew treatment allocation toward a treat-
ment as soon as one exhibits a certain advantage
over the other arms.
To illustrate the above point, let n0 and n1 be
the number of patients allocated to treatment 0
and 1 respectively, then for the results in Table 5
it holds that ECB(n0) = 31.60, E
CB(n1) = 116.40,
EWI(n0) = 16.49, E
WI(n1) = 131.51 and E
GI(n0) =
19.06, EGI(n1) = 128.94. Moreover, this implies that
the required “superiority” does not need to be
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Table 5
Comparison of different two-arm trial designs of size T = 148. Fa: Fisher’s adjusted test; α: type-I error; 1− β: power; p
∗:
expected proportion of patients in the trial assigned to the best treatment; ENS: expected number of patient successes; UB:
upper bound
Crit.
value
H0 : p0 = p1 = 0.3 H1 : p0 = 0.3, p1 = 0.5
α p∗ (s.e.) ENS (s.e.) 1− β p∗ (s.e.) ENS (s.e.)
FR 1.645 0.052 0.500 (0.04) 44.34 (5.62) 0.809 0.501 (0.04) 59.17 (6.03)
TS 1.645 0.066 0.499 (0.10) 44.39 (5.58) 0.795 0.685 (0.09) 64.85 (6.62)
UCB 1.645 0.062 0.499 (0.10) 44.30 (5.60) 0.799 0.721 (0.07) 66.03 (6.57)
RBI 1.645 0.067 0.502 (0.14) 44.40 (5.57) 0.763 0.737 (0.07) 66.43 (6.54)
RGI 1.645 0.063 0.500 (0.11) 44.40 (5.61) 0.785 0.705 (0.07) 65.46 (6.40)
CB Fa 0.046 0.528 (0.44) 44.34 (5.55) 0.228 0.782 (0.35) 67.75 (12.0)
WI Fa 0.048 0.499 (0.35) 44.37 (5.59) 0.282 0.878 (0.18) 70.73 (8.16)
GI Fa 0.053 0.501 (0.26) 44.41 (5.58) 0.364 0.862 (0.11) 70.21 (7.11)
UB 44.40 (0.00) 1 74.00 (0.00)
a statistically significant difference of the size in-
cluded in the alternative hypothesis as suggested by
the following values: ECBk (s/n) = [0.1437; 0.4208],
V CBk (s/n) = [0.1528; 0.1831], E
WI
k (s/n) = [0.1976;
0.4860], VWIk (s/n) = [0.1470; 0.08875], E
GI
k (s/n) =
[0.2283; 0.4959] and V GIk (s/n) = [0.1271; 0.0538].
The results in Table 5 illustrate the natural ten-
sion between the two opposing goals of maximizing
the statistical power to detect significant treatment
effects (using FR) and maximizing the health of the
patients in the trial (using GI). The optimality prop-
erty inherent in the GI design produces an average
gain in successfully treated patients of 11 (an im-
provement of 18.62% over the FR design). This is
only 4 fewer patients on average than the theoretical
upper bound (calculated as T × p1 = 74) achievable
if all patients were assigned to the best treatment
from the start. It is worth noting that the asymptoti-
cally optimal index approaches [w.r.t. (2.4)] improve
on the statistical power of the index designs (around
76%–78% for a 5% type-I error rate) at the expense
of attaining an inferior value of ENS (around 5 fewer
successes on average compared to the bandit-based
rules). Yet, these rules significantly improve on the
value of ENS attained by a FR design, naturally
striking a better balance in the patient health/power
trade-off.
From Table 5 one can see that the three index-
based rules significantly improve on the average
number of successes in the trial by increasing the
allocation toward the superior treatment based on
the observed data. This acts to reduce the power
to detect significant treatment effect. Another fac-
tor at play is bias: index-based rules induce a neg-
ative bias in the treatment effect estimates of each
arm, the magnitude of this bias is largest for inferior
treatments (for which less patients are assigned to
than superior treatments). When the control is in-
ferior to the experimental treatment, this induces a
positive bias in the estimated benefit of the exper-
imental treatment over the control. This is shown
in Figure 4. A heuristic explanation for this is as
follows. The index-based rules select a “superior”
treatment before the trial is over based on the accu-
mulated data. This implies that if a treatment per-
forms worse than its true average, that is, worse for
a certain number of consecutive patients, then the
treatment will not be assigned further patients. The
treatment’s estimate then has no chance to regress
up toward the true value. Conversely, if a treatment
performs better than its true average, the index-
based rules all assign further patients to receive it,
and its estimate then has the scope to regress down
toward its true value. This negative bias of the un-
selected arms is observed for all dynamic allocation
rules, and is the most extreme for the CB method.
The final observation refers to the fact that al-
though all the index-based rules fail to achieve the
required level of power to detect the true superior
treatment, they tend to correctly skew patient allo-
cation toward the best treatment within the trial,
when it exists. For the simulation reported in Ta-
ble 5 we have computed the probability that each
rule makes the wrong choice (i.e., stops allocating
patients to the experimental treatment). These val-
ues are as follows: 0.1730, 0.0307, 0.0035 for the CB,
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Fig. 4. Top: The bias in the control treatment estimate as a function of the number of allocated patients under H1. Bottom:
The bias in the experimental treatment estimate under H1.
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Table 6
Comparison of different four-arm trial designs of size T = 423. Fa: Fisher’s adjusted test; α: family-wise type-I error; 1− β:
power; p∗: expected proportion of patients in the trial assigned to the best treatment; ENS: expected number of patient
successes; UB: upper bound
Crit.
value
H0 : p0 = pi = 0.3 for i= 1, . . . ,3 H1 : p0 = pi = 0.3, i= 1,2, p3 = 0.5
α p∗ (s.e.) ENS (s.e.) (1− β) p∗ (s.e.) ENS (s.e.)
FR 2.128 0.047 0.250 (0.02) 126.86 (9.41) 0.814 0.250 (0.02) 148.03 (9.77)
TS 2.128 0.056 0.251 (0.07) 126.93 (9.47) 0.884 0.529 (0.09) 172.15 (13.0)
UCB 2.128 0.055 0.251 (0.06) 126.97 (9.41) 0.877 0.526 (0.07) 171.70 (11.9)
RBI 2.128 0.049 0.250 (0.03) 126.77 (9.40) 0.846 0.368 (0.04) 158.34 (10.4)
RGI 2.128 0.046 0.250 (0.03) 126.80 (9.36) 0.847 0.358 (0.03) 157.26 (10.3)
CB Fa 0.047 0.269 (0.39) 126.89 (9.61) 0.213 0.677 (0.41) 184.87 (36.8)
GI Fa 0.048 0.248 (0.18) 126.68 (9.40) 0.428 0.831 (0.10) 198.25 (13.7)
CG 2.128 0.034 0.250 (0.02) 127.16 (9.46) 0.925 0.640 (0.08) 182.10 (12.3)
UB 126.90 (0.00) 1 211.50 (0.00)
5.2 Multi-Arm Trial Setting
We now present results for a K = 4 setting. First,
we consider the case of a trial with T = 423 patients.
As before, we set the size of the trial to ensure that
a FR design results in at least 80% power to detect
an effective treatment for a family-wise error rate of
less than 5%. Results for this case are depicted in
Table 6. The Whittle index approach is omitted be-
cause for T roughly larger than 150 its performance
is near identical to that attained by the Gittins in-
dex but with a significantly higher computational
cost.
In this setting, the randomized and semi-
randomized adaptive rules (i.e., TS, UCB, RBI,
RGI) exhibit an advantage over a FR both in the
achieved power and in ENS. The reason for that
is that these rules continue to allocate patients to
all arms while they skew allocation to the best per-
forming arm, hence, ensuring that by the end of the
design the control arm will have a similar number of
observations than with FR while the best arm will
have a larger number. Among these rules, TS and
UCB exhibit the best balance between power-ENS
which achieve the 80% power increasing ENS in ap-
proximately 23 over a FR design. The deterministic
index-based rules CB and GI increase this advan-
tage in ENS over a FR design by roughly 36 and 50,
respectively. However, a severe reduction is again
observed in the power values of these designs. On
the other hand, the probability that each of these
rules makes a wrong choice (i.e., it does not skew the
allocation toward the best experimental treatment)
is 0.2691 and 0.0051, respectively, for the CB and
GI.
5.3 The Controlled Gittins Index Approach
To overcome the severe loss of statistical power of
the Gittins index, we introduce, for the multi-arm
trial setting only, a composite design in which the
allocation to the control treatment is done in such a
way that one in every K patients is allocated to the
control group while the allocation of the remaining
patients among the experimental treatments is done
using the Gittins index rule. We refer to this design
as the controlled Gittins (CG) approach.
Based on the simulation results, CG manages to
solve the trade-off quite successfully, in the sense
that it achieves more than 80% power, while it
achieves a mean number of successes very close to
the one achieved by the CB rule and with a third of
the variability that CB exhibits in expected number
of patient successes.
5.4 Multi-Arm Trial in a Rare Disease Setting
Finally, we imagine a rare disease setting, where
the number of patients in the trial is a high pro-
portion of all patients with the condition, but is
not enough to guarantee reasonable power to de-
tect a treatment effect of a meaningful size. In such
a context, the idea of prioritizing patient benefit
over hypothesis testing is likely to raise less con-
troversy than in a common disease context (Wang
and Arnold, 2002). We therefore simulate a four-
arm trial as before but where the size of the trial
is T = 80. Given that the size of the trial implies
a very small number of observations per arm, Ta-
ble 7 only includes the results of the tests using
Fisher’s exact test and Fisher’s adjusted exact test
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Table 7
Comparison of different four-arm trial designs of size T = 80. F: Fisher; α: type-I error; 1− β: power; p∗: expected
proportion of patients in the trial assigned to the best treatment; ENS: expected number of patient successes; UB: upper bound
Crit.
value
H0 : p0 = pi = 0.3 for i= 1, . . . ,3 H1 : pk = 0.3 + 0.1× k, k= 0,1,2,3
α p∗ (s.e.) ENS (s.e.) (1− β) p∗ (s.e.) ENS (s.e.)
FR F 0.019 0.251 (0.04) 24.01 (4.07) 0.300 0.250 (0.04) 35.99 (4.41)
TS F 0.013 0.250 (0.07) 24.01 (4.15) 0.246 0.338 (0.08) 38.34 (4.68)
UCB F 0.011 0.252 (0.06) 24.00 (4.12) 0.218 0.362 (0.08) 38.84 (4.71)
RBI F 0.018 0.250 (0.03) 23.97 (4.06) 0.295 0.268 (0.03) 36.52 (4.41)
RGI F 0.017 0.250 (0.02) 24.07 (4.07) 0.298 0.265 (0.03) 36.45 (4.36)
CB Fa 0.017 0.270 (0.30) 23.98 (4.08) 0.056 0.419 (0.38) 40.92 (6.89)
WI Fa 0.015 0.258 (0.22) 23.00 (4.14) 0.101 0.537 (0.31) 42.65 (6.02)
GI Fa 0.000 0.251 (0.13) 23.97 (4.11) 0.002 0.492 (0.21) 41.60 (5.44)
CG Fa 0.015 0.253 (0.13) 24.04 (4.13) 0.349 0.393 (0.16) 38.29 (4.82)
UB 24.00 (0.00) 1 48.00 (0.00)
(in this case, adjusted to attain the same type-I error
as the other methods). Also, to make the scenario
more general, we have considered that under the al-
ternative hypothesis the parameters are such that
H1 : pk = 0.3 + 0.1× k, k = 0,1,2,3.
The FR approach exhibits a 30% power and at-
tains an ENS value of 36. Table 7 shows the results
attained for each of the designs considered. Under
the alternative hypotheses, the GI and WI designs
achieve an ENS gain over the FR design of 6 pa-
tients. Again, the CG rule exhibits an advantage
over FR both in the achieved power and in the ENS
(which in the case of this small population equals
the advantage achieved by TS or UCB). Its ENS is
less than 10 below the theoretical upper bound of
48. An important feature to highlight is that the
Whittle rule does not significantly differ from the
Gittins rule as it could be expected, given the trial
(and hence its horizon) is small. These results il-
lustrate how the GI and WI start skewing patient
allocation toward the best arm (when it exists) ear-
lier than other adaptive designs, therefore explain-
ing their advantage in terms of p∗ for small T over
all of them.
6. DISCUSSION
Multi-armed bandit problems have emerged as the
archetypal model for approaching learning problems
while addressing the dilemma of exploration versus
exploitation. Although it has long been used as the
motivating example, they have yet to find any real
application in clinical trials. After reviewing the the-
ory of the Bernoulli MABP approach, and the Git-
tins and Whittle indices in particular, we have at-
tempted to illustrate their utility compared to other
methods of patient allocation in several multi-arm
clinical trial contexts.
Our results in Section 5 show that the Gittins
and Whittle index-based allocation methods per-
form extremely well when judged solely on patient
outcomes, compared to the traditional fixed ran-
domization approach. The two indexes have distinct
theoretical properties, yet in our simulations any dif-
ferences in their performances were negligible, with
both designs being close to each other and the best
possible scenario in terms of patient benefit. Since
it only needs to be calculated once before the trial
starts, the Gittins index may naturally be preferred.
The Gittins index, therefore, represents an ex-
tremely simple—yet near optimal—rule for allocat-
ing patients to treatments within the finite horizon
of a real clinical trial. Furthermore, since the index
is independent of the number of treatments, it can
seamlessly incorporate the addition of new arms in
a trial, by balancing the need to learn about the new
treatment with the need to exploit existing knowl-
edge on others. The issue of adding treatment arms
is present in today’s cutting-edge clinical trials. For
example, this facet has been built into the I-SPY
2 trial investigating tumour-specific treatments for
breast cancer from the start (Barker et al., 2009). It
is also now being considered in the multi-arm multi-
stage STAMPEDE trial into treatments for prostate
cancer as an unplanned protocol amendment, due to
a new agent becoming available (Sydes et al., 2009;
Wason et al., 2012).
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Gittins indices and analogous optimality results
have been derived for endpoints other than bi-
nary. Therefore, the analysis and conclusions of
this work naturally extend to the multinomial dis-
tribution (Glazebrook, 1978), normally distributed
processes with known variance (Jones, 1970) and
with unknown variance (Jones, 1975), and expo-
nentially distributed populations (Do Amaral, 1985;
Gittins, Glazebrook and Weber, 2011).
Unfortunately, the frequentist properties of de-
signs that utilize index-based rules can certainly be
questioned; both the Gittins and Whittle index ap-
proaches required an adjustment of the Fisher’s ex-
act test in order to attain type-I error control, pro-
duced biased estimates and, most importantly, had
very low power to detect a treatment difference at
the end of the trial. Since this latter issue greatly re-
duces their practical appeal, we proposed a simple
modification that acted to stabilize the numbers of
patients allocated to the control arm. This greatly
increased their power while seemingly avoiding any
unwanted type-I error inflation above the nominal
level. This principle is not without precedence, in-
deed, Trippa et al. (2012) have recently proposed
a Bayesian adaptive design in the oncology setting
for which protecting the control group allocation is
also an integral part. Further research is needed to
see whether statistical tests can be developed for
bandit-based designs with well-controlled type-I er-
ror rates and also if bias-adjusted estimation is pos-
sible.
There are of course other obvious limitations to
the use of index-based approaches in practice. A pa-
tient’s response to treatment needs to be known be-
fore the next patient is recruited, since the subse-
quent allocation decision depends on it. This will
only be true in a small number of clinical contexts,
for example, in early phase trials where the out-
come is quick to evaluate or for trials where the
recruitment rate may be slow (e.g., some rare dis-
ease settings). MABPs rely on this simplifying as-
sumption for the sake of ensuring both tractabil-
ity and optimality, and can not claim these special
properties without making additional assumptions
(see, e.g., Caro and Yoo, 2010). It would be interest-
ing to see, however, if index-based approaches could
be successfully applied in the more general settings
where patient outcomes are observed in groups at a
finite number of interim analyses, such as in a multi-
arm multi-stage trial (Magirr, Jaki and Whitehead,
2012; Wason and Jaki, 2012). Further research is
needed to address this question.
A different limitation to the use of bandit strate-
gies is found in the fact that the approach leads
to deterministic strategies. Randomization naturally
protects designs against many possible sources of
bias, for example, patient drift unbalancing treat-
ment arms (Tang et al., 2010) or unscrupulous trial
sponsors cherry-picking patients (FDA, 2006). Of
course, while these are serious concerns, they could
also be leveled at any other deterministic allocation
rule, such as play-the-winner. Further research is
needed to introduce randomization to bandit strate-
gies and also to determine some general conditions
under which arms are selected or dropped when us-
ing the index rules.
Further supporting materials for this paper,
including programs to calculate extended
tables of the Gittins and Whittle indexes, can be
found at http://www.mrc-bsu.cam.ac.uk/software/
miscellaneous-software/.
APPENDIX: INDEX COMPUTATION
There is a vast literature on the efficient computa-
tion of the Gittins indices. In Beale (1979), Varaiya,
Walrand and Buyukkoc (1985) and Chen and Kate-
hakis (1986), among others, algorithms for comput-
ing the Gittins indices for the infinite-horizon classic
MABP with a finite state space are provided. The
computational cost for all of them (in terms of its
running time as a function of the number of states
N ) is N3 + O(N2). The algorithm for computing
the Gittins indices in such a case achieving the low-
est time complexity, 2/3N3 +O(N2), was provided
by Nin˜o-Mora (2007). For MABP with an infinite
state space, such as the Bayesian Bernoulli MABP
in Section 3, the indices can be computed using any
of the above algorithms but confining attention to
some finite set of states, which will eventually deter-
mine the precision of their calculation. For the finite-
horizon classic MABP, as reviewed in Section 4,
an efficient exact computation method based on a
recursive adaptive-greedy algorithm is provided in
Nin˜o-Mora (2011).
In what follows we examine in more detail the so-
called calibration method for the approximate index
computation in the Bayesian Bernoulli MABP, both
for the infinite- (Gittins index) and finite-horizon
case (Whittle index). There are many reasons for fo-
cusing on this approach, not least because it was the
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algorithm used for computing the values presented
in this paper. It also sheds light on the interpre-
tation of the resulting index values, by connecting
the Gittins index approach to the work in Bellman
(1956), and has long been the preferred computa-
tional method.
The Calibration Method
Bellman (1956) studied an infinite random sam-
pling problem involving two binomial distributions:
one with a known success rate and the other one
with an unknown rate but with a Beta prior. Bell-
man’s key contribution was to show that the so-
lution to the problem of determining the sequence
of choices that maximize the ETD number of suc-
cesses exists, is unique and, moreover, is expressible
in terms of an index function which depends only on
the total observed number of successes s and failures
f of the unknown process.
Gittins and Jones (1974) used that result and
showed that the optimal rule for an infinite-horizon
MABP can also be expressed in terms of an index
function for each of the K Bernoulli populations and
based on their observed sampling histories (s, f).
Such an index function is given by the value p ∈ [0,1]
for which the decision maker is indifferent between
sampling the next observation from a population
with known success rate p or from an unknown one
with an expected success rate s
s+f . The calibration
method uses DP to approximate the Gittins index
values based on this idea, as explained in Gittins
and Jones (1979), and it can be adapted to com-
pute the finite-horizon counterpart, as explained in
Berry and Fristedt (1985), Chapter 5.
Specifically, this index computation method solves,
for a grid of p values (the size of which determines
the accuracy of the resulting index values approxi-
mations), the following DP problem:
V ∗D,t(s, f, p)
= max
{
p
1− dT−t
1− d
,
s
s+ f
(1 + dV ∗D,(t+1)(s+ 1, f, p))
(A.1)
+
f
s+ f
(dV ∗D,(t+1)(s, f + 1, p))
}
,
t= 0, . . . , T − 2,
V ∗D,T−1(s, f, p) = max
{
p,
s
s+ f
}
.
For the infinite-horizon problem and with 0≤ d < 1,
the convergence result allows for the omission of the
subscript t in the optimal value functions in (A.1),
letting the reward associated to the known arm be
p
(1−d) . For obtaining a reasonably good initial ap-
proximation of the optimal value function, the ter-
minal condition on V ∗D,T−1(s, f, p) is solved for some
values of s and f such that s + f = T − 1, and
for a large T and then a backward induction algo-
rithm is applied to yield an approximate value for
V ∗D,0(s, f, p). For a fixed p the total number of arith-
metic operations to solve (A.1) is 1/2(T −1)(T −2),
which, as stated in Section 3.1, no longer grows ex-
ponentially in the horizon of truncation T (nor does
it grow in the number of arms of the MABP).
For the finite-horizon variant, the terminal condi-
tion is not used for approximating the initial point
of the backward-induction algorithm and the solu-
tion, but for computing the optimal value function
exactly. The resulting number of operations to com-
pute the Whittle index is basically the same as for
the Gittins index, yet the total computational cost
is significantly higher given that the Whittle indices
must be computed and stored for every possible
t≤ T − 1 and (s, f). However, notice that an impor-
tant advantage of the Whittle index over the Gittins
index is that the discount factor d= 1 can be explic-
itly considered for the former directly adopting an
Expected Total objective function, by replacing the
term 1−d
T−t
1−d by T − t, using the fact that
lim
d→1
1− dT−t
1− d
=
T−t−1∑
i=0
di.
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